Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia +10 more·2016·Cell

DOI 10.1016/j.cell.2016.02.065

Cited by (1,009)

Items 401–500 of 1,009

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Chan-Young Ock, Jun‐Eul Hwang, Bhumsuk Keam, Sang-Bae Kim, Jae‐Jun Shim, Hee-Jin Jang, Sarang Park, Bo Hwa Sohn, Minse Cha, Jaffer A. Ajani et al. · 2017 · Nature Communications
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang · 2018 · Translational Oncology
Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
Haoyu Lyu, Mengyuan Li, Zehang Jiang, Zhixian Liu, Xiaosheng Wang · 2019 · Computational and Structural Biotechnology Journal
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
Yongfeng Wu, Jinming Xu, Chengli Du, Yihua Wu, Dajing Xia, Wang Lv, Jian Hu · 2019 · Frontiers in Oncology
Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data
Jinfen Wei, Kaitang Huang, Zixi Chen, Meiling Hu, Yunmeng Bai, Shudai Lin, Hongli Du · 2020 · Cancers
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
Haixia Long, Qingzhu Jia, Liuyang Wang, Wen‐Feng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Jin Zheng, Jiani Huang, Li Zhou et al. · 2022 · Cancer Cell
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Kathleen Margaret Mahoney, Sachet Ashok Shukla, Nikolaos Patsoukis, Apoorvi Chaudhri, Edward P. Browne, Arnon Arazi, Thomas Eisenhaure, William F. Pendergraft, Ping Hua, Hung C. Pham et al. · 2018 · Cancer Immunology Immunotherapy
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
Jeffrey C. Thompson, Wei‐Ting Hwang, Christiana W. Davis, Charuhas G. Deshpande, Seth Jeffries, Yashoda Rani Rajpurohit, Vinod Krishna, Denis S. Smirnov, Raluca I. Verona, Matthew V. Lorenzi et al. · 2019 · Lung Cancer
iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction
Bicheng Ye, Jun Fan, Lei Xue, Zhuang Yu, Peng Luo, Aimin Jiang, Jiaheng Xie, Qifan Li, Xiaoqing Liang, Jiaxiong Tan et al. · 2025 · iMeta
Acquired resistance in cancer: towards targeted therapeutic strategies
Alice Soragni, Erik S. Knudsen, Thomas N. O’Connor, Cristina E. Tognon, Jeffrey W Tyner, Beatrice Gini, Donghwa Kim, Trever Grant Bivona, Xingxing Zang, Agnieszka Katarzyna Witkiewicz et al. · 2025 · Nature reviews. Cancer
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
Julian Philipp Layer, Marie Kronmüller, Thomas Quast, Debby Konijnenberg, Maike Effern, Daniel Hinze, Kristina Althoff, Alexander R. Schramm, Frank Westermann, Martin Peifer et al. · 2017 · OncoImmunology
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Aravindhan Ganesan, Marawan Ahmed, Isobel Okoye, Elena I Arutyunova, Dinesh Babu, William L. Turnbull, Joydeb Kumar Kundu, Justin A. Shields, Katharine Cheryl Agopsowicz, Lai Xu et al. · 2019 · Scientific Reports
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
Julieta Afonso, Lúcio Lara Santos, Adhemar Longatto‐Filho, Fátima Baltazar · 2020 · Nature Reviews Urology
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
Jung Yong Hong, Hee Jin Cho, Jason K. Sa, Xiao Liu, Sang Yun Ha, Taehyang Lee, Hajung Kim, Wonseok Kang, Dong Hyun Sinn, Geum‐Youn Gwak et al. · 2022 · Genome Medicine
Bispecific dendritic-T cell engager potentiates anti-tumor immunity
Yuval Shapir Itai, Oren Barboy, Ran Salomon, Akhiad Bercovich, Ken Xie, Eitan E. Winter, Tamar Shami, Ziv Porat, Neta Erez, Amos Tanay et al. · 2024 · Cell
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik, Sara Moufarrij, Alejandro Villagra · 2019 · International Journal of Molecular Sciences
Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy
Zicheng Zhang, Lu Chen, Hongyan Chen, Jing Zhao, Ke Li, Jie Sun, Meng Zhou · 2022 · EBioMedicine
Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications
Eiji Yuba · 2020 · Journal of Materials Chemistry B
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang, Sixue Liu, Zhentao Yang, Alain Patrick Algazi, Shirley H. Lomeli, Yan Wang, Megan K. D. Othus, Aayoung Hong, Xiaoyan Wang, Christopher E. Randolph et al. · 2021 · Cancer Cell
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
Hussein A. Abbas, Dapeng Hao, Katarzyna J. Tomczak, Praveen Barrodia, Jin Seon Im, Patrick Kevin Reville, Zoe Alaniz, Wei Wang, Ruiping Wang, Feng Wang et al. · 2021 · Nature Communications
Mechanisms of Resistance to Immune Checkpoint Blockade
David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher, Mike F. Burbridge · 2017 · Current Oncology Reports
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation
Xiao, Qian, Wu, Jibo, Wang, Wei-Jia, Chen, Shiyang, Zheng, Yingxia, Yu, Xiaoqing, Meeth, Katrina, Sahraei, Mahnaz, Bothwell, Alfred L M, Chen, Lieping et al. · 2018 · Nature Medicine
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander M.M. Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Palich Fucikova, Jérôme Galon, Aurélien Marabelle et al. · 2015 · OncoImmunology
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Qin Fan, Zhipeng Chen, Chao Wang, Zhuang Liu · 2018 · Advanced Functional Materials
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Zhe Fu, Alexandra M. Mowday, Jeff Bruce Smaill, Ian F. Hermans, Adam Vorn Patterson · 2021 · Cells
Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy
Lequeux, Audrey, Noman, Muhammad Zaeem, Xiao, Malina, Van Moer, Kris, Hasmim, Meriem, Benoit, Alice, Bosseler, Manon, Viry, Elodie, Arakelian, Tsolere, Berchem, Guy et al. · 2021 · Oncogene
A clonal expression biomarker associates with lung cancer mortality
Dhruva Biswas, Nicolai J. Birkbak, Rachel Rosenthal, Crispin T. Hiley, Emilia L. Lim, Krisztián Papp, Stefan Boeing, Marcin Krzystanek, Dijana Djureinovic, Linnéa La Fleur et al. · 2019 · Nature Medicine
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Tianrui Yang, Ziren Kong, Wenbin Ma · 2020 · Human Vaccines & Immunotherapeutics
Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
Maria Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Patricia V. Elizalde, Roxana Schillaci · 2021 · Cancers
Targeting immunosuppression by TGF-β1 for cancer immunotherapy
Grégoire de Streel, Sophie Lucas · 2021 · Biochemical Pharmacology
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Hannah Noelle Bell, Weiping Zou · 2024 · Annual Review of Immunology
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
François Bertucci, Anthony Gonçalvès · 2017 · Current Oncology Reports
Recent updates on cancer immunotherapy
Ming Liu, Fukun Guo · 2018 · Precision Clinical Medicine
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
Daniël A. Lionarons, David C. Hancock, Sareena Rana, Philip East, Christopher Moore, Miguel Manuel Murillo, Joana Carvalho, Bradley Spencer‐Dene, Eleanor Herbert, Gordon Stamp et al. · 2019 · Cancer Cell
Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review
Kevin Dzobo, Dimakatso Alice Senthebane, Chelene Ganz, Nicholas Ekow Thomford, Ambroise Wonkam, Collet Dandara · 2020 · Cells
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Xin Hong, Ryan Joseph Sullivan, Mark Kalinich, Tanya Todorova Kwan, Anita Giobbie‐Hurder, Shiwei Pan, Joseph A. LiCausi, John D. Milner, Linda T. Nieman, Ben S. Wittner et al. · 2018 · Proceedings of the National Academy of Sciences
PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis
Yan Geng, Xue Liu, Jiurong Liang, David M. Habiel, Vrishika Kulur, Ana Lúcia Coelho, Nan Deng, Ting Xie, Yizhou Wang, Ningshan Liu et al. · 2019 · JCI Insight
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
Hao‐Xiang Wu, Zixian Wang, Qi Zhao, Dongliang Chen, Ming-Ming He, Lu-Ping Yang, Yingnan Wang, Ying Jin, Chao Ren, Hui Luo et al. · 2019 · Annals of Translational Medicine
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
María Tello‐Lafoz, Katja Srpan, Elisa E. Sanchez, Jing Ying Hu, Ján Remšík, Yevgeniy Romin, Annalisa Calò, Douglas Robert Hoen, Umesh Kumar Bhanot, Luc G.T. Morris et al. · 2021 · Immunity
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Dan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, Luke Anderson-Trocmé, Marine Lingrand, Diana Berry, Lucas J. M. Perus, Yuhong Wei, Cleber Moraes, Rached Alkallas et al. · 2022 · Science Immunology
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts
Yushen Wu, Ziying Yi, Jie Li, Yuxian Wei, Rui Feng, Jiazhou Liu, Jiefeng Huang, Yuru Chen, Xiaoyu Wang, Jiazheng Sun et al. · 2022 · Theranostics
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
Lee A. Albacker, Jeremy Wu, Peter G. Smith, Markus Warmuth, Philip J. Stephens, Ping Zhu, Lihua Yu, Juliann Chmielecki · 2017 · PLoS ONE
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Gustavo Bergerot, Peter Lamb, Evelyn W. Wang, Sumanta Kumar Pal · 2019 · Molecular Cancer Therapeutics
Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
Richard Peck · 2017 · The Annual Review of Pharmacology and Toxicology
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Maarten Alexander Ligtenberg, Stéphanie A. Blankenstein, Beaunelle de Bruijn, Dennie Tompers Frederick, Juliana C.N. Kenski, Mara Parren, Marieke Brüggemann et al. · 2020 · Nature Communications
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Sawsan Sudqi Said, Wisam Nabeel Ibrahim · 2023 · Pharmaceutics
Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath Devin Skinner, Uma P. Giri, Liang Peng Yang, Manish Kumar, Ying Liu, Michael D. Story, Curtis R. Pickering, Lauren A. Byers, Michelle D. Williams, Jing Wang et al. · 2017 · Clinical Cancer Research
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Guo-Liang Chew, Amy E. Campbell, Emma De Neef, Nicholas A. Sutliff, Sean C. Shadle, Stephen J. Tapscott, Robert K. Bradley · 2019 · Developmental Cell
The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer
N. Bercovici, M. Guérin, A. Trautmann, E. Donnadieu · 2019 · Frontiers in Immunology
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Elaine R. Mardis · 2019 · Genome Medicine
KIT and Melanoma: Biological Insights and Clinical Implications
Duc Daniel M. Pham, Samantha M. Guhan, Hensin Tsao · 2020 · Yonsei Medical Journal
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Binita Chakraborty, Jovita K. Byemerwa, Jonathan Shepherd, Corinne Haines, Robert Baldi, Weida Gong, Wen Liu, Debarati Mukherjee, Sandeep Artham, Felicia Lim et al. · 2021 · Journal of Clinical Investigation
A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome
Hebert Alberto Vargas, Harini Veeraraghavan, Maura Miccò, Stéphanie Nougaret, Yulia Lakhman, Andreas A. Meier, Ramon E. Sosa, Robert A. Soslow, Douglas A. Levine, Britta Weigelt et al. · 2017 · European Radiology
Computational Prediction and Validation of Tumor-Associated Neoantigens
Vladimir Roudko, Benjamin D. Greenbaum, Nina Bhardwaj · 2020 · Frontiers in Immunology
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Zuzana Macek Jílková, Caroline Aspord, Thomas Decaens · 2019 · Cancers
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam F. Sinjab, Humam N. Kadara · 2020 · Frontiers in Immunology
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Eva Pérez‐Guijarro, Howard Hua Yang, Romina Elizabeth Araya, Rajaâ El Meskini, Helen T. Michael, Suman Kumar Vodnala, Kerrie L. Marie, Cari Smith, Sung Chin, Khiem Chi Lam et al. · 2020 · Nature Medicine
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer
Han Chen, Han Liang · 2020 · Cancer Cell
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Xueping Wang, Fang Wang, Mengjun Zhong, Yosef Yarden, Liwu Fu · 2020 · Molecular Cancer
Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation
Wanzun Lin, Li Chen, Haojiong Zhang, Xianxin Qiu, Qingting Huang, Fangzhu Wan, Ziyu Le, Shikai Geng, Anlan Zhang, Sufang Qiu et al. · 2023 · Nature Communications
ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
Lin Li, Mengyuan Li, Zehang Jiang, Xiaosheng Wang · 2019 · Cells
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Martina Musella, Andrea Guarracino, Nicoletta Manduca, Claudia Galassi, Eliana Ruggiero, Alessia Potenza, Ester Maccafeo, Gwenola Manic, Luca Mattiello, Sara Soliman Abdel Rehim et al. · 2022 · Nature Immunology
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
Veronica Finisguerra, Tereza Dvořáková, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion, Bernard Gallez, Benoit J. Van den Eynde · 2023 · Journal for ImmunoTherapy of Cancer
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy
Qi Zhang, Bo Zhu, Yongsheng Li · 2017 · Frontiers in Immunology
A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
Yohei Takeda, Keisuke Kataoka, Junya Yamagishi, Seishi Ogawa, Tsukasa Seya, Misako Matsumoto · 2017 · Cell Reports
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic · 2021 · Seminars in Cancer Biology
Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
Zhao, Fei, Evans, Kathy, Xiao, Christine, DeVito, Nicholas, Theivanthiran, Balamayooran, Holtzhausen, Alisha, Siska, Peter J., Blobe, Gerard C., Hanks, Brent A. · 2018 · Cancer Immunology Research
Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers
Lisa Sevenich · 2019 · Frontiers in Oncology
Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy
Haodi Zhao, Jing Wei, Jian M. Sun · 2020 · International Immunopharmacology
Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy
Qihang Yuan, Dawei Deng, Pan Chen, Jie Ren, Tianfu Wei, Zeming Wu, Biao Zhang, Shuang Li, Peiyuan Yin, Dong Shang · 2022 · Frontiers in Immunology
Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
Zhewen Xiong, Stephen Lam Chan, Jingying Zhou, Joaquim S. L. Vong, Tsz Tung Kwong, Xuezhen Zeng, Haoran Wu, Jian Cao, Yalin Tu, Yu Feng et al. · 2023 · Gut
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Pınar Ö. Eser, Pasi Antero Janne · 2017 · Pharmacology & Therapeutics
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, Isabel Shu Ying Tay, Xinru Lim, Bernett Teck Kwong Lee, Valerie Chew, Huihua Li, Benedict Tan, Sherlly Lim et al. · 2020 · Journal for ImmunoTherapy of Cancer
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
Jeffrey C. Thompson, Christiana W. Davis, Charuhas G. Deshpande, Wei‐Ting Hwang, Seth Jeffries, Alexander Chan Chi Huang, Tara C. Mitchell, Corey Jay Langer, Steven Μ. Albelda · 2020 · Journal for ImmunoTherapy of Cancer
Turning tumors from cold to inflamed to improve immunotherapy response
Camille Lea Gerard, Julie Delyon, Alexandre M. Wicky, Krisztián Homicskó, Michel A. Cuendet, Olivier Alain Michielin · 2021 · Cancer Treatment Reviews
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
Julia Joung, Paul C. Kirchgatterer, Ankita Singh, Jang Hwan Cho, Suchita P. Nety, Rebecca C. Larson, Rhiannon K. Macrae, Rebecca Deasy, Yuen‐Yi Tseng, Marcela Valderrama Maus et al. · 2022 · Nature Communications
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S.Y. Cindy Yang, Scott C. Lien, Ben X. Wang, Derek Clouthier, Youstina Hanna, Iulia Cirlan, Kelsey Zhu, Jeffrey P. Bruce, Samah El Ghamrasni, Marco Adelmo James Iafolla et al. · 2021 · Nature Communications
The influence of microenvironment on tumor immunotherapy
Jieying Zhang, Zhaopeng Shi, Xiang Xu, Zuoren Yu, Jun Mi · 2019 · FEBS Journal
The complementarity of DDR, nucleic acids and anti-tumour immunity
Anand V. R. Kornepati, Cody M. Rogers, Patrick Sung, Tyler Jay Curiel · 2023 · Nature
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Maria Anna Smolle, Horatiu N. Calin, Martin Pichler, George A. Călin · 2017 · FEBS Journal
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D. Galsky, Huan Wang, Noah M. Hahn, Przemyslaw W. Twardowski, Sumanta Kumar Pal, Costantine Albany, Mark T. Fleming, Alexander Starodub, Ralph J. Hauke, Menggang Yu et al. · 2017 · European Urology
Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Sathya Muralidhar, Anastasia Filia, Jérémie Nsengimana, Joanna Poźniak, Sally Jane O'Shea, Joey Mark S. Diaz, Mark Harland, Juliette A. Randerson‐Moor, Jörg Reichrath, Jonathan P. Laye et al. · 2019 · Cancer Research
Endogenous T cells prevent tumor immune escape following adoptive T cell therapy
Scott R. Walsh, Boris Simovic, Lan Chen, Donald J. Bastin, Andrew Nguyen, Kyle B. Stephenson, Talveer S. Mandur, Jonathan L. Bramson, Brian Dennis Lichty, Yonghong Wan · 2019 · Journal of Clinical Investigation
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Merope Griffin, Daniele Scotto, Debra Hannah Josephs, Silvia Mele, Silvia Crescioli, Heather J. Bax, Giulia Pellizzari, Matthew D. Wynne, Mano Nakamura, Ricarda M. Hoffmann et al. · 2017 · Oncotarget
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
Yan Kong, Canqiang Xu, Chuanliang Cui, Wenxian Yang, Shuang Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Rongshan Yu et al. · 2021 · npj Genomic Medicine
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier, Jason Madore, Jake S. O’Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth McDonald, Elizabeth Stephanie Ahern, Anna Kuchel, Melissa A. Eastgate, Sally‐Ann Pearson et al. · 2020 · Clinical Cancer Research
Transcriptomics and solid tumors: The next frontier in precision cancer medicine
Apostolia Maria Tsimberidou, Elena Fountzilas, Leonidas G. Bleris, Razelle Kurzrock · 2020 · Seminars in Cancer Biology
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Francesca Di Modugno, Cristina Colosi, Paola Trono, Giuseppe Antonacci, Giancarlo Ruocco, Paola Nisticò · 2019 · Journal of Experimental & Clinical Cancer Research
BRAF Gene and Melanoma: Back to the Future
Margaret Ottaviano, Emilio Francesco Giunta, Marianna Tortora, Marcello Curvietto, Laura Attademo, Davide Bosso, Cinzia Cardalesi, Mario Rosanova, Pietro De Placido, Erica Pietroluongo et al. · 2021 · International Journal of Molecular Sciences
Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes
Allison, Katrina E., Coomber, Brenda L., Bridle, Byram W. · 2017 · Immunology
Mechanisms of Drug Resistance in Melanoma
Matthew L. Winder, Amaya Virós · 2017 · Handbook of experimental pharmacology
PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene
Kristin Berger, Jeffrey J. Pu · 2017 · Gene
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Aaron Michael Goodman, Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul J. Riviere, Garrett Michael Frampton, Ethan S. Sokol, Xinlian Zhang, Edward David Ball et al. · 2020 · Genome Medicine
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response
Guangyu Wang, Dandan Xu, Zicheng Zhang, Xia Li, Jie Sun, Jie Sun, Xiaobo Li, Xiaobo Li, Meng Zhou, Tongsen Zheng · 2021 · npj Precision Oncology
Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response
Alexander Coulton, Jun Murai, Danwen Qian, Krupa Thakkar, Claire E. Lewis, Kevin Litchfield · 2024 · Nature Communications
Mechanisms of Tumor Cell–Intrinsic Immune Evasion
Stefani Spranger, Thomas Frank Gajewski · 2017 · Annual Review of Cancer Biology
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
Mingdong Lu, Bin Zhao, Mengshan Liu, Le Wu, Yingying Li, Yingna Zhai, Xian Shen · 2021 · npj Precision Oncology
Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1
Chan‐Hyeong Lee, Ju-Hyun Bae, Eunji Choe, Ju‐Mi Park, Seong‐Sik Park, Hee Jin Cho, Byoung‐Joon Song, Moon‐Chang Baek · 2022 · Theranostics
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, Xiao Chen, Tessa M. Firestone, Allison R. Hickman, Wendy Mao, Tanay Thakar, Alina Vaitsiankova, Jen‐Wei Huang et al. · 2024 · Cell